208:poster Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial

• Peter Vickerman,
• Kjell Arne Johansson,
• Lars Thore Fadnes,
• Christer Frode Aas,
• Aaron G Lim,
• Ege Su Çağlar,
• Jørn-Henrik Vold

Affiliations

Peter Vickerman

University of Bristol, Bristol, UK

Kjell Arne Johansson

Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Lars Thore Fadnes

Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway

Christer Frode Aas

1 Department of Addiction Medicine, Helse Bergen HF, Bergen, Norway

Aaron G Lim

1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Ege Su Çağlar

2Bergen Addiction Research group, Department of Addiction Medicine, Haukeland University Hospital, Østre Murallmenningen 7, N-5012 Bergen, Norway

Jørn-Henrik Vold

2Bergen Addiction Research group, Department of Addiction Medicine, Haukeland University Hospital, Østre Murallmenningen 7, N-5012 Bergen, Norway